Haloperidol Lactate
Trade name
Serenace
Strength
5 mg/mL (volume: 1 mL)
IV administration
IM route is preferred. Refer to relevant local guideline for intravenous use.
Use undiluted or dilute with a compatible fluid and give as a slow IV injection over 3 – 5 minutes.
Loading doses can be given over 30 to 45 minutes.
May also be given as an intermittent or continuous infusion.
Other routes of administration
IM: Suitable and preferred route. Give undiluted by deep IM injection.
SC: Suitable. May be given as an intermittent or continuous SC infusion in palliative care settings.
Compatible IV fluids
Haloperidol lactate 3 mg/mL or weaker:
Glucose 5%
Haloperidol lactate 0.75 mg/mL or weaker:
Sodium chloride 0.9%
Additional information
Use IV route only when facilities for cardiac monitoring and cardio-respiratory resuscitation exist.
Monitor ECG before, during and for 2 to 3 hours after IV administration.
Use contraindicated in patients predisposed to QT interval prolongation or in patients being administered other medications known to prolong the QT interval.
IV administration is associated with a greater risk of QT prolongation.
May lower the seizure threshold, use cautiously in patients with seizure history.
Concomitant use of CNS depressants (e.g. opioids, parenteral benzodiazepines, IM olanzapine) increases the risk of respiratory depression, sedation, coma and death.
Protect from light during storage.